Drug intelligence / Profile preview

LR004

Development stage: Unknown
Lead developer: Xingmeng Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LR004 is a recombinant monoclonal antibody targeting the epidermal growth factor receptor (EGFR), developed by Shenzhen Longrui Pharmaceutical. It is designed to treat advanced solid tumors by binding to the extracellular domain of EGFR, thereby inhibiting ligand binding and subsequent downstream signaling pathways (such as MAPK and PI3K/Akt) that promote tumor cell proliferation, survival, and metastasis. It has been investigated in Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetics in patients with advanced malignancies.

Other names: LR-004LR004LR 004Synermore SYN004

Targets

FCGRT (Neonatal crystallizable fragment receptor)C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on LR004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR004.

Explore the full profile